CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo

CD44-specific short peptide A6 boosts cellular uptake and anticancer efficacy of PEGylated liposomal doxorubicin in vitro and in vivo

Abstract Although liposomes have improved patient safety and the pharmacokinetic profile of free drugs, their therapeutic efficacy has only shown marginal improvement. The incorporation of active-targeted ligands to enhance cellular uptake has shown promise in preclinical studies. However, no active...

Full description

Bibliographic Details
Main Authors: Rezvan Yazdian-Robati, Ehsan Amiri, Hossein Kamali, Aysun Khosravi, Seyed Mohammad Taghdisi, Mahmoud Reza Jaafari, Mohammad Mashreghi, Seyedeh Alia Moosavian
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Cancer Nanotechnology
Subjects:
A6 peptide
Liposomes
Targeted therapy
Cancer
Doxorubicin
Online Access:https://doi.org/10.1186/s12645-023-00236-0

Internet

https://doi.org/10.1186/s12645-023-00236-0

Similar Items